Is overexpression of HER-2 a predictor of prognosis in colorectal cancer?

Background: The development of novel chemotherapeutic agents in colorectal cancer has improved survival. Following initial response to chemotherapeutic strategies many patients develop refractory disease. This poses a significant challenge common to many cancer subtypes.